Clinical Trials Logo

Vaccinia clinical trials

View clinical trials related to Vaccinia.

Filter by:

NCT ID: NCT01144637 Completed - Smallpox Clinical Trials

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Start date: February 2013
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, placebo-controlled Phase III trial to evaluate immunogenicity and safety of three consecutive production lots of IMVAMUNE® (MVA-BN®) smallpox vaccine in healthy, vaccinia-naïve subjects.

NCT ID: NCT00857493 Completed - Smallpox Clinical Trials

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

Start date: June 2009
Phase: Phase 2
Study type: Interventional

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-Experienced Subjects

NCT ID: NCT00629759 Completed - Neoplasms, Liver Clinical Trials

A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma

Start date: January 2006
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to determine the maximum tolerable dose (MTD) and/or the maximum feasible dose (MFD), as well as to evaluate the safety of JX-594 (Pexa-Vec) injected within hepatic carcinoma tumors.

NCT ID: NCT00625456 Completed - Lung Cancer Clinical Trials

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors

Start date: June 2008
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, dose-escalation trial in patients with advanced/metastatic solid tumors refractory to standard therapy; tumors may include malignant melanoma, non-small cell lung cancer, renal cell carcinoma, and squamous cell carcinoma of the head and neck. These tumor types were selected because evidence of biological activity was observed in these tumor types in a Phase I study of JX-594 (Pexa-Vec) administered by intratumoral injection in patients with metastatic disease to the liver. Patients will receive treatment at one of five dose levels in a sequential dose-escalating design.

NCT ID: NCT00574977 Completed - Breast Cancer Clinical Trials

Safety Study of Modified Vaccinia Virus to Cancer

Start date: May 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and maximum tolerated dose from injecting this vaccinia virus into tumors or infusion.

NCT ID: NCT00554372 Completed - Clinical trials for Carcinoma, Hepatocellular

A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma

Start date: August 2008
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine whether JX-594 (Pexa-Vec) has significant anti-tumoral activity and tolerability in primary hepatocellular carcinoma and to determine the dose to be used in further testing.

NCT ID: NCT00429312 Completed - Melanoma Clinical Trials

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

Start date: March 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this research study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma.

NCT ID: NCT00407069 Completed - Atopic Dermatitis Clinical Trials

Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus

Start date: June 2005
Phase: N/A
Study type: Observational

Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by recurrent viral skin infections. Recent studies have demonstrated that the skin of people with AD my have decreased antimicrobial peptide (AMP) expression. The purpose of this study is to compare smallpox virus replication and the number of AMPs and other antiviral molecules in people with AD, as compared to those seen in people with psoriasis or asthma, or healthy individuals.

NCT ID: NCT00301184 Completed - HIV Infections Clinical Trials

Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults

Start date: April 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety of and immune response to a DNA HIV vaccine, pGA2/JS7, followed by a modified vaccinia (smallpox) HIV vaccine, MVA/HIV62, in HIV uninfected adults.

NCT ID: NCT00116597 Completed - Melanoma Clinical Trials

Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma

Start date: November 2002
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess intranodal immunotherapy in locally advanced to metastatic melanoma patients (American Joint Committee on Cancer [AJCC] stages IIb to IV). For this, the investigators capitalize on their previous melanoma clinical trial (published by Zajac P et al in Human Gene Ther 2003) and take advantage of a proprietary recombinant vaccinia virus (replication inactivated) expressing 5 minigenes: 3 melanoma associated antigens and 2 costimulatory molecules. Immunization with the recombinant vaccinia virus is followed by 3 boosts with soluble, synthetic melanoma associated antigens. The patients are immunized intranodally (groin lymph node) under ultrasonographic guidance in an outpatient clinic. The protocol foresees 2 cycles of immunotherapy for alternate weeks and lasts 15 weeks.